Medicare AdvantageBilling CodesMedium impact
MA07.032a, Tumor Treating Fields
Independence Blue Cross·Oncology, Neurosurgery, Radiation Oncology·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross Medicare Advantage reissued policy MA07.032a on Tumor Treating Fields, adding CPT code 1025T (alternating electric fields dosimetry and delivery) effective 01/01/2026. The policy maintains existing coverage criteria for newly diagnosed glioblastoma (TTFields device E0766) and non-coverage for recurrent disease, implanted devices, and other cancer types. Billing teams must recognize the new CPT code as medically necessary and update systems to include it in TTFields claims.
Action Required
By 01/01/2026: Billing team must update billing system and fee schedules to recognize CPT code 1025T (alternating electric fields dosimetry and delivery-simulation modeling) as a medically necessary code for newly diagnosed glioblastoma cases under Medicare Advantage. Ensure claims submission includes 1025T when TTFields treatment (E0766) is billed. Verify that A4555 (electrode/transducer replacement) remains excluded from separate reimbursement in system edits. Update coding guidelines and staff training materials to reference this policy change. Flag any historical claims denying 1025T for reconsideration if within appeal timelines.